Clinical Trial Update: Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 window-of-opportunity study evaluating durvalumab (MEDI4736) in operable non-small cell lung cancer. The study ai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: Yonsei University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING